Clopidogrel and vascular disease prevention

Authors: Stella S. Daskalopoulou¹; Gerard Stansby²; Dimitri P. Mikhailidis¹

Source: Current Medical Research and Opinion, Volume 20, Number 11, November 2004 , pp. 1835-1838(4)

Buy & download fulltext article:

Price: $51.50 plus tax (Refund Policy)

Abstract:

In this editorial we consider some aspects of the use of clopidogrel in current clinical practice.

Clopidogrel has replaced ticlopidine as an alternative to aspirin. Among the problems with the use of antiplatelet agents is aspirin intolerance. The options for these patients are discussed; these include using clopidogrel.

Clopidogrel may be especially effective in patients with peripheral arterial disease. However, this impression requires confirmation in appropriately designed trials.

We also consider the effect of antiplatelet agents on growth factor release by platelets and of clopidogrel on the inflammatory process.

Clopidogrel is a useful, evidence-based, antiplatelet agent.

Keywords: ANTIPLATELET AGENTS; ASPIRIN; ATORVASTATIN; CLOPIDOGREL; PLATELET; STATINS; VASCULAR DISEASE

Document Type: Editorial

DOI: http://dx.doi.org/10.1185/030079904X10656

Affiliations: 1: Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, Royal Free and University College Medical School, London, UK 2: Northern Vascular Unit and University Department of Surgery, Newcastle upon Tyne, UK

Publication date: 2004-11-01

More about this publication?